GSK falls in line with Big Pharma's reaction to Ukraine invasion, cutting off new clinical trials, donating profits and more

Just a few days after multiple Big Pharmas such as Bayer and Pfizer started the de-facto Big Pharma response to Russian aggression in Ukraine, other global players such as Novartis and Eli Lilly started to follow suit, pushing beyond its first tentative steps with a full-throated commitment to severing business ties with Russia wherever possible.

Now another one of the handful of holdouts is piling on: London-based GlaxoSmithKline. The pharma — helmed by Emma Walmsley — announced overnight that the company has taken a few actions in Russia.